---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Scenario analyses"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Scenario analyses. Topics: Avacincaptad pegol PBAC financial estimates: continued monthly dosing after year 1 and Pegcetacoplan PBAC financial estimates: revisions to scripts and uptake. 2 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics/scenario-analyses"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Scenario analyses

<a id="heading-4.2.6.2"></a>

## 4.2.6.2 Scenario Analyses

<a id="topic-4.2.6.2-1"></a>

### Budget impact model of vonaprument: scenario analyses

No evidence found.

<a id="topic-4.2.6.2-2"></a>

### Avacincaptad pegol PBAC financial estimates: continued monthly dosing after year 1

> “Scenario 1: 50% of patients continue EM dosing after year 1”
> “Scenario 2: 100% of patients continue EM dosing after year 1”
> “The ESC noted that while the estimated cost to the PBS/RPBS remained the same in year 1 ($20 million to < $30 million), the estimated cost increased to $70 million to < $80 million in year 6 with a cumulative cost of $300 million to < $400 million over the first 6 years of listing.”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="topic-4.2.6.2-3"></a>

### Pegcetacoplan PBAC financial estimates: revisions to scripts and uptake

> “The PBAC agreed with the DUSC that the number of pegcetacoplan scripts per year was underestimated.”
> “The PBAC considered that, with these amendments and with the price reduction required to achieve cost effectiveness outlined in paragraph 7.15, it would be reasonable to accept the financial estimates as the basis of a risk sharing arrangement.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
